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Backgroud: Soshiho-tang (SST, Xiao-chai-hu-tang in Chinese and Sho-saiko-to in Japanese), an oriental herbal
formula, is used for treatment of chronic liver diseases. Although many researchers have studied the
pharmacological properties of SST, information about its safety and toxicity is limited. Therefore, we evaluated the
potential safety of SST in Sprague–Dawley rats over a period of 4-weeks.
Methods: The SST was administered once daily by gavage to male and female rats at doses of 0, 500, 1000 and
2000 mg/kg/day for 4 weeks. We measured the body weight, mortality, food consumption, ophthalmoscopy,
urinalysis, hematology, serum biochemistry, gross pathological findings, absolute/relative organ weights and
histopathology. In addition, we analyzed the component of SST and measured the stability of its component in SST
according to study periods using high performance liquid chromatography.
Results: The SST treatment did not result in any toxicologically significant changes in mortality, food consumption,
ophthalmoscopy, urinalysis, hematology, serum biochemistry, gross pathological findings, absolute/relative organ
weights and histopathology, except for salivation and reduction in body weight in the 2000 mg/kg/day male
group. These findings in the 2000 mg/kg/day male group are considered toxicologically insignificant because they
are not accompanied by other pathological findings, including in hematology, serum biochemistry and
histopatholgy, and they do not exhibit a dose–response relationship. SST is detected three components including
liquiritin, baicalin, and glycyrrhizin. In addition, there were not observed the significant differences among the
contents of three components in SST according to storage periods.
Conclusion: These results indicate that SST may be a safe material. Based on these results, the no-observed-
adverse-effect level was more than 2000 mg/kg for both genders.
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Herbal formulas are traditionally used in Korea, China
and Japan. The preparation of formulas is a form of
oriental herbology, in which herbs are combined to
achieve greater efficacy than is possible with individual
herbs alone. Such herbal formulas are used for treatment
of various disorders that can be considered chronic by
clinical standards. Many researchers have investigated the
properties of herbal formulas in a range of experimental* Correspondence: hkshin@kiom.re.kr
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reproduction in any medium, provided the orsystems. In addition, patients and physicians use herbal
formulas to supplement the treatment of diseases with
Western-style medicines [1,2]. However, the toxicity and
quality control of herbal formulas for public consumption
are one of increasing concern because of the lack of
scientific evidence on their safety. Indeed, few studies
have explored the safety and toxicity of herbal formulas,
generating concerns regarding their potential adverse
effects [3,4]. This has led to an urgent need to evaluate the
safety of herbal formulas through basic science or clinical
trials, to provide the essential information required for
their clinical use.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Sho-saiko-to in Japanese), an oriental herbal formula, is
commonly used in Korea, China and Japan. It consist of
seven herbs: Bupleurum falcatum, Pinellia ternate,
Scutellaria baicalensis, Zizyphus jujuba, Panax ginseng,
Glycyrrhiza uralensis and Zingiber officinale. According
to previous studies, SST exhibits various pharmaco-
logical properties including anti-inflammatory [5], anti-
oxidant [6], immunomodulatory [7], hepatoprotective
[8], anti-hepatic fibrotic [9], and antitumoral effects [10].
In particular, SST has been shown in both basic and
clinical studies to have powerful protective effects via
modulation of the immune response to hepatic viral
infection in diseases such as chronic viral hepatitis C
[11-13]. Indeed, SST is traditionally used for treatment
of chronic hepatitis, liver cirrhosis and various chronic
inflammatory diseases [14].
Although SST has been found to have a variety of
pharmacological effects, few scientific studies have
examined its safety and toxicity. Therefore, we evaluated
the toxicity of a 4-week repeated oral dose of SST in
Sprague–Dawley (SD) rats to establish its safety and
toxicity profiles of SST. In addition, we analyzed the
components in SST by high performance liquid chro-
matogram (HPLC) and evaluated the stability of SST
according to storage periods by measuring the contents of
components. The present study was conducted accord-
ing to guidelines established by the Organization for
Economic Cooperation and Development (OECD) for
the testing of chemicals in accordance with the current
regulations for Good Laboratory Practice Regulations.
Methods
Preparation of SST
The SST consisting of seven herbal medicines (Table 1)
and each crude drug was purchased from Omniherb
(Yeongcheon, Korea) and HMAX (Jecheon, Korea). The
origin of materials was confirmed taxonomically by Prof.
Je-Hyun Lee of Dongguk University (Gyeongju, Republic
of Korea) and Prof. Young-Bae Seo of Daejeon University
(Daejeon, Republic of Korea). A decoction of SST was pre-
pared in our laboratory (Table 1, 38.46 kg) from a mixtureTable 1 The composition of SST
Latin name Amount (g) Ratio
Bupleuri Radix 11.25 6
Pinelliae Tuber 7.5 4
Scutellariae Radix 3.75 2
Ginseng Radix Alba 3.75 2
Zizyphi Fructus 3.75 2
Zingiberis Rhizoma Crudus 3.75 2
Glycyrrhizae Radix 1.875 1
Total 35.625of chopped crude herbs, extracted in distilled water at
100°C for 2 h in an herb extractor (COSMOS-660,
Kyungseo Machine Co., Incheon, Korea). The solution
was filtration using a standard sieve (No. 270, 53 μm) and
freeze-dried (6.30 kg). The yield of SST extract was 16.37%.
The yield of Soshiho-tang extract was 16.37%. For HPLC
analysis, lyophilized SST extract (200 mg) was dissolved in
distilled water (20 mL). The solution was filtered using a
syringe filter (0.2 μm, Woongki Science, Seoul, Korea).Reagents
The two flavonoids, liquiritin and baicalin, and one tri-
terpenoid saponin glycoside, glycyrrhizin were purchased
from Wako (Osaka, Japan). The purity of each compo-
nent was determined to be above 98% by HPLC analysis.
HPLC-grade reagents, methanol, acetonitrile, and water
were obtained from J.T.Baker (Phillipsburg, NJ, USA).
Glacial acetic acid was of analytical reagent grade,
procured from Junsei (Tokyo, Japan).Linearity, limits of detection (LOD) and quantification
(LOQ)
Standard stock solutions of liquiritin, baicalin, and glycyr-
rhizin were dissolved in methanol in the concentration of
1.0 mg/mL and stored below 4°C. Working standard solu-
tions were prepared by serial dilution of stock solutions
with methanol. Calibration curves of three compounds
were calculated by peak areas of standard solutions in the
concentration of 3.91–250.00 μg/mL. The LOD and LOQ
data obtained under the chromatographic conditions used
in the present study were determined using signal-to-
noise (S/N) ratios of 3 and 10, respectively.Stability
The stabilities of liquiritin, baicalin, and glycyrrhizin
were determined by six injections with sample solution
during 10 days (0, 1, 2, 5, 7, and 10 day, respectively). In
addition, we measure the stabilities of liquiritin, baicalin,
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A Shimadzu LC-20A HPLC system (Shimadzu Co.,
Kyoto, Japan) consisting of a solvent delivery unit, an
on-line degasser, a column oven, an autosampler, and a
PDA detector. The data processor employed LCsolution
software (Version 1.24). The analytical column used
was a Gemini C18 (250×4.6 mm; particle size 5 μm,
Phenomenex, Torrance, CA, USA). The mobile phases
consisted of (A) 1.0%, v/v, aqueous acetic acid and (B)
acetonitrile with 1.0%, v/v, acetic acid. The gradient flow
was as follows: (A)/(B)=85/15 (0 min) → (A)/(B)=60/40
(15 min) → (A)/(B)=45/55 (40 min) → (A)/(B)= 0/100
(50 min; hold for 5 min) → (A)/(B)= 85/15 (55 min;
hold for 15 min). Column temperature was maintained
at 30°C. The analysis was carried out at a flow rate of
1.0 mL/min with PDA detection at 254 and 275 nm.
The injection volume was 10 μL.
Animal
Twenty 4-weeks-old SD rats of each sex were obtained
from Orient Bio Co. (Seoul, Korea), a specific pathogen-
free facility, and used after 2 weeks of quarantine and
acclimatization. The animals were housed in a room
maintained at 22 ± 3°C under a relative humidity of
50 ± 20% with artificial lighting from 08:00 to 20:00 and
12–15 air changes per hour. Three animals were kept in
stainless-steel wire-mesh cages and allowed sterilized tap
water and commercial rodent chow (PMI Nutrition
International, Richmond, USA) ad libitum. This study
was approved by Korea Institute of Oriental Medicine
Institutional Animal Care and Use Committee and was
performed at the Korea Institute of Toxicology (Daejeon,
Korea) and conducted according to the guidance of the
Institutional Animal Care and Use Committee in Korea
Institute of Toxicology (KRICT) (accredited by AAALAC
International, 1998) under the Good Laboratory Practice
Regulations for Nonclinical Laboratory Studies.
Experimental groups and treatment
Healthy male and female rats were assigned to four
groups using Path/Tox System 4.2.2 (Xybion Medical
Systems Corporation, USA). Each group consisted of five
rats of each sex. Before performing this study, we con-
ducted the acute toxicity study according to OECD
guideline. As results of acute toxicity study, SST did not
exhibit any adverse effects at dose level of up to 2000
mg/kg in both genders. Based on these results, we estab-
lished 2000 mg/kg/day as the maximum dose, with 500
mg/kg/day and 1000 mg/kg/day as low and medium
doses, respectively. The SST was prepared fresh on each
treatment day the vehicle-only control group received an
equal volume of distilled water. Because oral administra-
tion is the clinically intended route for SST, it was admi-
nistered by oral gavage in the present study. The dailydose (10 ml/kg body weight) of SST was calculated
based on the most recently recorded body weights of
individual animals.
General observations
Clinical signs and mortality were recorded twice a day
(before and after treatment) throughout the study
period. All clinical signs were recorded individually for
type, observation day/time and duration using Path/Tox
System 4.2.2 (Xybion Medical Systems Corporation,
USA). The body weight of each rat was measured at the
initiation of treatment and once a week during the study
period. Food consumption was measured at the start of
treatment and weekly throughout. Daily food consump-
tion was determined by measuring the weight of chow
supplied and remaining each day. External eye examin-
ation was carried out during the last week of treatment
with an indirect binocular ophthalmoscope (IO-H, Neitz
Instrument Co., Japan), and the appearance of the
conjunctiva, sclera, cornea, lens, and iris of each eye was
recorded.
Urinalysis, hematology and serum biochemistry
During the last week of treatment, urinalysis was
conducted on samples collected overnight using a
Multistix 10 SG (Bayer, USA) and urine chemical
analyzer (Clinitek-500, USA). Analysis included volume,
specific gravity (SG), pH, protein, ketone body (KET),
occult blood (BLO), glucose, bilirubin (BIL), nitrite
(NIT), urobilinogen (URO) and sediment.
Animals were fasted overnight prior to blood collec-
tion or necropsy. Blood was drawn from the posterior
vena cava under isoflurane anesthesia. Samples were
collected in CBC bottles containing EDTA-2K (Sewon
Medical Co., Republic of Korea), and were analyzed to
determine red blood cell count (RBC), white blood cell
count (WBC), differential WBC count, hemoglobin
concentration (HGC), hematocrit (HCT), mean corpus-
cular volume (MCV), mean corpuscular hemoglobin
(MCH), mean corpuscular hemoglobin concentration
(MCHC), platelet (PLT) and reticulocyte (RET) using an
ADVIA120 Hematology System (Bayer, USA). Prothrom-
bin time (PT) and activated partial thromboplastin time
(APTT) were determined in blood samples treated with
3.2% sodium citrate using a coagulometer (ACL 300
plus, Instrumentation Laboratory, Italy).
For serum biochemistry, blood samples were centri-
fuged at 3000 rpm for 10 min and analyzed with an
autoanalyzer (Toshiba 200FR NEO, Toshiba Co., Japan).
The analysis included alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase
(ALP), gamma glutamyl transpeptidase (GGT), blood
urea nitrogen (BUN), creatinine (CREA), creatine kinase
(CK), glucose (GLU), total cholesterol (TCHO), albumin
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triglyceride (TG), total bilirubin (TBIL), phospholipids
(PL), sodium (Na), potassium (K), calcium (Ca), chloride
(Cl) and inorganic phosphorus (IP).
Necropsy
All surviving animals were anesthetized with isofluorane
and sacrificed by aortic exsanguination prior to nec-
ropsy. Complete gross postmortem examinations were
performed on all animals. Absolute organ weights were
measured and relative organ weights (organ-to-body
weight ratios) were calculated for the following organs:
brain, pituitary gland, adrenal gland, liver, spleen,
kidneys, heart, thymus, lung, salivary gland, thyroids,
testes, ovaries, epididymides, seminal vesicle, prostate
and uterus.
Histopathological examination
Liver and kidney samples were fixed in 10% neutral
buffered formalin, embedded in paraffin, sectioned at
4 μm and stained with hematoxylin (Sigma MHS-16)
and eosin (Sigma HT110-1-32). Tissues were subse-
quently mounted and coverslipped using Dako mounting
medium (Invitrogen, USA).
Statistical analysis
Data collected during the study were examined for
the variance homogeneity using Bartlett’s test. When
Bartlett’s test indicated no significant deviation from the
variance homogeneity, a one-way ANOVA was per-
formed at α=0.05. When significance was noted, a mul-
tiple comparison test (Dunnett’s test) was conducted to
determine which pairs of groups were significantly
different. Where significant deviations from variance
homogeneity were observed, a nonparametric compari-
son test (Kruskal–Wallis test) was conducted. When a
significant difference was observed in the Kruskal–
Wallis test, the Dunn’s Rank Sum test was conducted to
determine the specific pairs. Statistical analyses were
performed using the Path/Tox System (ver. 4.2.2). The
level of significance was taken as p<0.05 or 0.01.
Results
Clinical signs and mortality
In female rats, no clinical signs were observed (data not
shown). By contrast, in male rats, salivation was
observed in all animals in the 2000 mg/kg group, and in
one case in the 500 mg/kg and 1000 mg/kg groups.
Death did not occur in either sex at any dose, or in the
vehicle-only control group.
Body weight changes and food consumption
There was no significant difference in body weights be-
tween the vehicle-only control group and the treatmentgroups in females (Figure 1). However, for the 2000 mg/kg
male group, body weight was significantly reduced on days
15, 22 and 28, and for the 1000 mg/kg male group, there
was a significant reduction on day 28. No significant dif-
ferences were observed in food consumption between the
vehicle-only control and treatment groups for either sex
(data not shown). In addition, ophthalmologic examina-
tions did not reveal treatment related ocular lesions in any
of the animals (data not shown).
Necropsy findings
There were no treatment-related gross pathological
changes at necropsy, with the exception of a size reduc-
tion in epididymides (n = 1), prostate (n = 1) and testes
(n = 1) in the 1000 mg/kg male group (data not shown).
In females, no gross pathological findings were observed
in any group.
For absolute organ weights, the 2000 mg/kg male
group showed significant reductions in pituitary gland,
liver, lung and thyroid/parathyroid (data not shown). In
female groups, there was no significant difference in
absolute organ weights between the vehicle-only control
and treatment groups (data not shown). Finally, there
was no significant difference in relative organ weights
between the vehicle-only control and treatment groups
for either sex (Table 2).
Hematology serum biochemistry and urinalysis
No significant differences were noted with hematology
tests in any female group. In contrast, the 2000 mg/kg
male group showed a significant increase in percent
neutrophils (Table 3). However, there was no significant
difference in serum biochemical (Table 4) and urinalysis
values (data not shown) between the vehicle-only con-
trol and treatment groups.
Histopathological examination
Administration of SST did not induce histopathological
changes in liver or kidney at any dose level (data not
shown).
Linearity, range, LOD and LOQ
The linearity of the peak area (y) versus concentration
(x, μg/mL) curve for reference compounds such as
liquiritin, baicalin, and glycyrrhizin was used to calculate
the contents of the main components in Soshiho-tang.
The correlation coefficients (R2) of the calibration curves
for seven constituents were ≥0.9993. The regression
equations were Y = 20031.34x – 19996.27 for liquiritin,
Y = 38806.45x – 79723.75 for baicalin, and Y = 8959.42x
– 15143.09 for glycyrrhizin. These results showed that
the calibration curve was a good linearity. The LODs
and LOQs were 0.09–0.21 μg/mL and 0.29–1.37 μg/mL,
respectively.
Figure 1 Body weight changes of male and female rat treated with SST for 4-weeks. (A) body weight changes of males, (B) body weight
changes of female. *,** Indicate a significant differences at P < 0.05 and P < 0.01 levels, respectively, when compared with the vehicle control
group.
Table 2 Relative organ weights male rats treated with SST for 4 weeks
Dose (mg/kg/day) 0 500 1000 2000
Males
Brain 0.54 ± 0.04 a 0.58 ± 0.05 0.54 ± 0.03 0.59 ± 0.01
Pituitary gland 0.003 ± 0.0003 0.003 ± 0.0006 0.003 ± 0.0003 0.002 ± 0.0005
Liver 3.25 ± 0.12 3.15 ± 0.21 3.06 ± 0.15 3.05 ± 0.15
Spleen 0.19 ± 0.01 0.19 ± 0.03 0.20 ± 0.03 0.18 ± 0.03
Heart 0.33 ± 0.02 0.34 ± 0.02 0.34 ± 0.02 0.34 ± 0.02
Thymus 0.14 ± 0.03 0.16 ± 0.05 0.15 ± 0.03 0.11 ± 0.01
Salivary glands 0.17 ± 0.01 0.17 ± 0.02 0.17 ± 0.01 0.19 ± 0.02
Seminal vesicle 0.36 ± 0.08 0.41 ± 0.11 0.33 ± 0.06 0.38 ± 0.04
Prostate 0.13 ± 0.02 0.13 ± 0.01 0.13 ± 0.02 0.12 ± 0.02
Kidneys 0.85 ± 0.06 0.82 ± 0.03 0.83 ± 0.05 0.83 ± 0.05
Adrenal glands 0.017 ± 0.002 0.015 ± 0.002 0.016 ± 0.002 0.017 ± 0.003
Testes 0.89 ± 0.04 0.88 ± 0.13 0.88 ± 0.14 0.87 ± 0.05
Epididymides 0.27 ± 0.03 0.27 ± 0.05 0.27 ± 0.02 0.26 ± 0.02
lung 0.41 ± 0.03 0.40 ± 0.04 0.39 ± 0.02 0.38 ± 0.03
Thyroid/Parathyroid 0.006 ± 0.001 0.005 ± 0.001 0.006 ± 0.001 0.005 ± 0.001
Females
Brain 0.90 ± 0.05 0.85 ± 0.10 0.87 ± 0.03 0.87 ± 0.02
Pituitary gland 0.006 ± 0.0009 0.005 ± 0.0005 0.006 ± 0.0010 0.005 ± 0.0009
Liver 3.25 ± 0.16 3.23 ± 0.13 3.25 ± 0.26 3.36 ± 0.10
Spleen 0.22 ± 0.04 0.21 ± 0.02 0.23 ± 0.03 0.24 ± 0.02
Heart 0.36 ± 0.02 0.35 ± 0.01 0.37 ± 0.02 0.37 ± 0.02
Thymus 0.19 ± 0.02 0.18 ± 0.03 0.21 ± 0.04 0.21 ± 0.04
Salivary glands 0.19 ± 0.02 0.19 ± 0.01 0.19 ± 0.01 0.21 ± 0.02
Kidneys 0.85 ± 0.04 0.85 ± 0.02 0.85 ± 0.08 0.94 ± 0.07
Adrenal glands 0.034 ± 0.004 0.029 ± 0.001 0.032 ± 0.005 0.034 ± 0.004
Ovaries 0.042 ± 0.004 0.040 ± 0.005 0.041 ± 0.009 0.040 ± 0.005
Lung 0.53 ± 0.02 0.51 ± 0.03 0.51 ± 0.05 0.50 ± 0.04
Thyroid/parathyroid 0.007 ± 0.002 0.006 ± 0.001 0.007 ± 0.001 0.008 ± 0.001
Uterus/cervix 0.23 ± 0.03 0.26 ± 0.12 0.23 ± 0.07 0.32 ± 0.11
a Values are presented as mean ± SD.
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Table 3 Hematological values of animals treated with SST for 4 weeks
Dose (mg/kg/day) 0 500 1000 2000
Male rat
WBC (103/μL) 11.05 ± 2.35a 12.76 ± 1.78 12.68 ± 3.36 9.14 ± 2.40
Reticulocyte (%) 2.7 ± 0.42 2.7 ± 0.20 3.0 ± 0.73 2.3 ± 0.23
Neutrophils (%) 9.18 ± 2.34 11.28 ± 3.40 10.32 ± 2.35 14.60 ± 2.78*
Lymphocytes (%) 86.5 ± 3.26 81.9 ± 3.25 84.6 ± 2.67 80.1 ± 3.62*
Eosinophils (%) 0.8 ± 0.40 0.6 ± 0.09 0.6 ± 0.22 0.5 ± 0.12
Monocytes (%) 2.0 ± 0.59 2.7 ± 0.66 2.6 ± 0.63 2.6 ± 0.56
Basophils (%) 0.8 ± 0.20 1.1 ± 0.22 1.0 ± 0.21 1.3 ± 0.35
Large unstained cells (%) 0.7 ± 0.24 2.4 ± 2.97 0.9 ± 0.16 1.0 ± 0.34
RBC (106/μL) 8.04 ± 0.16 8.33 ± 0.43 8.15 ± 0.38 8.22 ± 0.55
Hemoglobin (g/dl) 15.8 ± 0.51 16.2 ± 0.58 16.1 ± 0.52 15.8 ± 0.49
Hematocrit (%) 47.7 ± 2.12 48.3 ± 1.98 48.1 ± 1.75 48.0 ± 1.76
MCV (fL) 59.2 ± 1.64 58.1 ± 1.68 59.0 ± 1.34 58.5 ± 1.79
MCH (pg) 19.6 ± 0.32 19.4 ± 0.61 19.8 ± 0.38 19.3 ± 0.75
MCHC (g/dl) 33.1 ± 0.37 33.5 ± 0.73 33.5 ± 0.44 32.9 ± 0.31
Platelet (103/μL) 1305 ± 225 1164 ± 40 1198 ± 67 1178 ± 66
PT (sec) 17.5 ± 0.86 17.2 ± 0.45 16.5 ± 0.87 16.7 ± 0.62
APTT (sec) 16.3 ± 0.80 16.7 ± 0.80 15.4 ± 1.11 16.3 ± 0.49
Female rat
WBC (103/μL) 8.07 ± 1.25 8.17 ± 2.38 8.27 ± 1.09 6.75 ± 0.56
Reticulocyte (%) 2.2 ± 0.38 2.7 ± 0.39 2.4 ± 0.58 2.5 ± 0.55
Neutrophils (%) 13.12 ± 6.54 15.92 ± 7.16 15.58 ± 5.63 13.20 ± 3.05
Lymphocytes (%) 81.6 ± 6.97 78.6 ± 7.19 79.2 ± 5.09 82.7 ± 2.81
Eosinophils (%) 1.0 ± 0.15 1.3 ± 0.38 1.1 ± 0.15 0.8 ± 0.17
Monocytes (%) 2.2 ± 0.86 2.6 ± 0.40 2.4 ± 0.61 1.7 ± 0.35
Basophils (%) 0.9 ± 0.21 0.8 ± 0.25 0.7 ± 0.13 0.9 ± 0.13
Large unstained cells (%) 1.2 ± 0.42 0.9 ± 0.23 1.0 ± 0.08 0.8 ± 0.26
RBC (106/μL) 8.24 ± 0.33 8.28 ± 0.16 8.18 ± 0.20 8.14 ± 0.13
Hemoglobin (g/dl) 15.9 ± 0.55 15.7 ± 0.44 16.0 ± 0.13 15.7 ± 0.19
Hematocrit (%) 46.4 ± 1.62 46.4 ± 1.06 47.0 ± 0.43 46.2 ± 0.73
MCV (fL) 56.4 ± 0.88 56.0 ± 1.67 57.5 ± 1.25 56.8 ± 0.49
MCH (pg) 19.3 ± 0.43 19.0 ± 0.54 19.6 ± 0.50 19.4 ± 0.35
MCHC (g/dl) 34.3 ± 0.28 33.9 ± 0.38 34.1 ± 0.40 34.1 ± 0.49
Platelet (103/μL) 1242 ± 76 1595 ± 430 1161 ± 100 1132 ± 32
PT (sec) 17.6 ± 0.43 18.1 ± 0.26 17.6 ± 0.59 18.3 ± 0.73
APTT (sec) 13.9 ± 0.39 15.4 ± 0.86 14.3 ± 1.10 14.8 ± 0.75
APTT, activated partial thromboplastin time; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin
concentration; PT, prothrombin time.
a Values are presented as mean ± SD.
* Indicate a significant difference at P < 0.05 level, when compared with the vehicle control group.
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The stability test of liquiritin, baicalin, and glycyrrhizin
was evaluated using the sample solution for 10 days and
4 weeks. In Table 5, sample solution retained a content
of 93.66–101.37% as compared with the initial content
at 0 day. The RSD values of contents about three
compounds in sample solution were within 1.59%. In
addition, there was no observed the significant differencein contents of three components according storage
periods of 4 weeks (Table 6).
HPLC analysis of SST
Our analysis method was applied to the simultaneous
determination of three compounds, liquiritin, baicalin,
and glycyrrhizin in Soshiho-tang. Figure 2 show chroma-
tograms of reference components and water extract of
Table 4 Serum biochemical values of animals treated with SST for 4 weeks
Dose (mg/kg/day) 0 500 1000 2000
Male rat
Glucose (mg/dL) 120.0 ± 14.95 131.6 ± 18.66 133.8 ± 24.86 122.4 ± 6.90
BUN (mg/dL) 14.0 ± 1.58 13.5 ± 1.09 12.9 ± 1.90 12.9 ± 1.60
Creatinine (mg/dL) 0.57 ± 0.05 0.55 ± 0.05 0.55 ± 0.03 0.58 ± 0.04
Total protein (g/dL) 6.42 ± 0.13 6.54 ± 0.17 6.19 ± 0.29 6.48 ± 0.20
Albumin (g/dL) 4.08 ± 0.06 4.12 ± 0.12 3.99 ± 0.09 4.09 ± 0.09
Albumin/globulin ratio 1.75 ± 0.11 1.70 ± 0.08 1.83 ± 0.15 1.71 ± 0.05
Total cholesterol (mg/dL) 52.0 ± 7.75 57.0 ± 8.51 57.6 ± 18.77 50.8 ± 6.42
Triglycerides (mg/dL) 32.1 ± 9.98 31.4 ± 9.83 36.5 ± 8.41 36.0 ± 9.96
Phospholipid (mg/dL) 86 ± 10.0 90 ± 5.1 87 ± 19.6 87 ± 11.3
AST (IU/L) 136.1 ± 20.74 152.0 ± 33.87 119.8 ± 14.15 157.6 ± 32.13
ALT (IU/L) 28.4 ± 2.67 36.2 ± 11.11 30.5 ± 3.22 32.7 ± 2.25
Total bilirubin (mg/dL) 0.13 ± 0.010 0.13 ± 0.004 0.12 ± 0.015 0.113 ± 0.015
ALP (IU/L) 590.0 ± 84.05 506.1 ± 104.95 521.4 ± 94.21 557 ± 52.56
Creatine kinase (IU/L) 872 ± 275 935 ± 321 759 ± 156 989 ± 327
Female
Glucose (mg/dL) 100.3 ± 28.10 89.1 ± 18.43 98.9 ± 10.13 108.1 ± 18.59
BUN (mg/dL) 18.7 ± 1.87 17.7 ± 1.89 15.6 ± 2.22 15.3 ± 2.26
Creatinine (mg/dL) 0.62 ± 0.05 0.65 ± 0.05 0.58 ± 0.07 0.60 ± 0.03
Total protein (g/dL) 6.96 ± 0.11 6.94 ± 0.16 6.79 ± 0.14 6.98 ± 0.21
Albumin (g/dL) 4.47 ± 0.15 4.45 ± 0.09 4.34 ± 0.04 4.48 ± 0.10
Albumin/globulin ratio 1.79 ± 0.11 1.79 ± 0.08 1.78 ± 0.07 1.80 ± 0.13
Total cholesterol (mg/dL) 73.2 ± 14.96 65.6 ± 8.23 60.2 ± 7.36 56.0 ± 17.18
Triglycerides (mg/dL) 27.3 ± 3.67 25.6 ± 1.54 29.1 ± 7.61 25.2 ± 5.98
Phospholipid (mg/dL) 124 ± 19.4 111 ± 9.8 106 ± 11.6 104 ± 21.5
ASP (IU/L) 160.3 ± 25.73 142.6 ± 9.32 155.9 ± 27.99 140.9 ± 33.54
ALT (IU/L) 25.7 ± 2.47 30.0 ± 5.14 25.3 ± 3.46 26.7 ± 4.66
Total bilirubin (mg/dL) 0.13 ± 0.014 0.13 ± 0.014 0.12 ± 0.011 0.13 ± 0.010
ALP (IU/L) 413.6 ± 61.29 432.5 ± 86.29 379.4 ± 40.70 383.6 ± 103.75
Creatine kinase (IU/L) 1127 ± 288 966 ± 196 1044 ± 263 947 ± 411
ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alkaline phosphatase; BUN, blood urea nitrogen.
a Values are presented as mean ± SD.
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The retention times of the three compounds were 13.00,
19.88, and 33.42 min for liquiritin, baicalin, and glycyr-
rhizin, respectively. The contents of three components
identified at 0, 1, and 4 weeks in Soshiho-tang were not
observed significant differences. These results were sum-















Liquiritin 2.8±0.04 1.59 2.8±0.00 0.03 2.8±0.01 0
Baicalin 60.9±0.04 0.06 60.9±0.04 0.07 60.0±0.26 0
Glycyrrhizin 2.3±0.01 0.63 2.3±0.03 1.14 2.3±0.02 0Discussion
In current biomedical research, many studies of thera-
peutic materials have been based on evidence-based
medicine (EBM). EBM aims to apply knowledge gained
from rigorous scientific research to find solutions to
problematic clinical issues [15]. In EBM, evidence of

















.34 2.8±0.01 0.44 2.6±0.00 0.05 2.7±0.01 0.50
.43 61.0±0.17 0.28 60.8±0.07 0.11 60.6±0.02 0.04
.65 2.3±0.00 0.07 2.4±0.00 0.17 2.3±0.01 0.45
Table 6 Contents of three components in the SST for 4 weeks by HPLC (n=3)
Compound 0 week 1 week 4 week
Mean (mg/g) SD RSD (%) Mean (mg/g) SD RSD (%) Mean (mg/g) SD RSD (%)
Liquiritin 2.71 0.01 0.42 2.66 0.03 0.98 2.57 0.02 0.82
Baiclin 61.58 0.02 0.04 60.16 0.28 0.46 57.19 0.38 0.66
Glycyrrhizin 2.33 0.00 0.11 2.54 0.01 0.59 2.43 0.03 1.43
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atic reviews [16]. Herbal medicines have become in-
creasingly popular in modern societies around the globe,
and many researchers have conducted pharmacological
studies on their constituents to strengthen the evidenceFigure 2 HPLC chromatogram of the standard mixture and SST with PDof efficacy. However, herbal medicines are often not
subjected to toxicity testing before human consumption
because they are widely considered inherently safe.
Recently, however, the potential for adverse effects of
herbal medicines in clinical usage has become anA detector (A) and UV–vis absorption spectra of compounds (B).
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gently needed to assess the safety of the wide array of
herbal medicines in use. In this study, we evaluated the
toxicity and safety of SST, which is used in Korea, China
and Japan for treatment of liver diseases. This evaluation
was done via a 4-week repeated-oral-dose toxicity study,
carried out in accordance with OECD guidelines. In
addition, we analyzed the components in SST and evalu-
ated the changes in contents of its components accor-
ding to storage period by HPLC. Present study showed
that administration of SST did not have any adverse
effects in SD rat of either sex, when given orally at 2000
mg/kg/day in both gender except for salivation and a re-
duction of body weight in 2000 mg/kg/day male group.
The components in SST including liquiritin, biacalin
and glycyrrhizin were no significant differences among
its contents according storage periods.
There were no treatment-related effects with regard to
food consumption, ophthalmoscopy, urinalysis, hematology,
serum biochemistry, testosterone concentration, gross
pathological findings, organ weight or histopathology,
regardless of sex. However, all animals in the 2000
mg/kg/day male group exhibited excess salivation. This
is considered to be related to SST treatment because it
occurred in a high incidence and exhibited a dose
response relationship. Furthermore, body weight was
significantly decreased in the male group treated with
2000 mg/kg SST in a dose response fashion, suggesting
that the reduction in body weight is caused by SST
administration. However, the reduction in body weight
of the 2000 mg/kg male group is considered to be of
relatively little toxicological significance because the
reduction caused is within the normal range, as estab-
lished by our histological data and previous studies
[18,19]. Further study is needed to determine whether
these changes are induced by certain pharmacological
properties or toxic effects of SST.
In absolute organ weights, significant differences were
observed in the pituitary gland, liver, lung and thyroid/
parathyroid of the 2000 mg/kg male group, compared
with the vehicle-only control. However, this change was
not considered an SST-induced abnormality because it
was not observed in females of the same dose group and
no dose dependent correlation was observed. Further-
more, this finding was not accompanied by relative
weight changes and gross pathological findings.
To date, there were few reports on the potential side
effects of SST. In Japan, some case reports have raised
concerns regarding interstitial pneumonia and acute re-
spiratory failure. Previous studies reported that patients
took SST for treating chronic liver diseases, which
caused interstitial pneumonia [20-22]. However, accord-
ing to Lee et al. [14], the incidence of side effects is
increased by other variables such as coadministration ofinterferon, the duration of SST treatment and increasing
age of patients. Indeed, it was concluded that it is very
difficult to determine whether the apparent side effects
are causally linked to SST administration.
To investigate the chemical analysis and stability of
SST according to periods, we have conducted HPLC
analysis of SST. Liquiritin, baicalin and glycyrrhizin were
detected in SST by HPLC analysis. These compounds
have possessed various benefit effects such as antioxida-
tive, antiinflammatory and antitumor effects proved by
many experiments [23-25]. The contents of three compo-
nents were not observed significant differences according
to storage periods. These findings indicate that SST may
be very safe material. In addition, this conclusion was sup-
ported by previous studies about toxicity studies of crude
herbs including Bupleuri Radix, Scutellariae Radix and
Ginseng Radix Alba [26-28]. Previous studies demon-
strated that three crude herbs did not any toxic effects on
repeated oral toxicity or genotoxicity studies.
Conclusion
As mentioned previously, SST is recommended for treat-
ment of chronic liver diseases, based on the results of
various clinical trials and pharmacological studies. How-
ever, little information is available on the safety and
toxicity of SST. The study demonstrates that SST does
not induce specific adverse effects in SD rats when used
in either sex at doses of up to 2000 mg/kg for 4 weeks.
In human, the single dose of SST is about 35.625 g dried
herbs, which is equivalent to 5.83 g of the SST extract
(yield = 16.37%). Based on an average body weight of an
adult of 60 kg, this dose for a 60 kg human is same as
97.2 mg of SST extract/kg [29,30]. This dosage is about
20-fold lower than high dose used in this study. Add-
itionally, whether the increased salivation and reduced
body weight were observed in males administered the
highest dose (2000 mg/kg males) represent important
side effects of SST can only be determined by further
pharmacological and toxicity studies.
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